Cabaletta Bio (CABA) Assets (2018 - 2026)
Cabaletta Bio (CABA) posted quarterly Assets of $165.1 million for Q4 2025, down 10.79% year-over-year from $185.0 million in Q4 2024, and down 13.0% quarter-over-quarter from $189.8 million in Q3 2025.
Cabaletta Bio (CABA) Assets (2018 - 2026) Analysis & Trends
Cabaletta Bio's Assets history runs 8 years deep, the most recent figure standing at $165.1 million for Q4 2025.
- In Q4 2025, Assets fell 10.79% year-over-year to $165.1 million; the TTM figure through Dec 2025 stood at $165.1 million (down 10.79% YoY), while the FY2025 annual figure was $165.1 million, down 10.79% from the prior year.
- Assets for Q4 2025 stood at $165.1 million, down from $189.8 million in the prior quarter.
- The five-year high for Assets was $253.6 million in Q4 2023, with the low at $91.7 million in Q3 2022.
- The 5-year median for Assets is $165.1 million (2025), against an average of $159.7 million.
- The sharpest annual moves came in 2024 and 2025: Assets jumped 132.44% in 2024, then tumbled 31.32% in 2025.
- Cabaletta Bio's Assets stood at $126.3 million in 2021, then dropped by 7.42% to $117.0 million in 2022, then soared by 116.85% to $253.6 million in 2023, then dropped by 27.05% to $185.0 million in 2024, then decreased by 10.79% to $165.1 million in 2025.
- Business Quant data shows CABA's Assets at $165.1 million in Q4 2025, $189.8 million in Q3 2025, and $224.5 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Cabaletta Bio | 466.25 Mn | 466.25 Mn | - | 256.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 256.73 Mn |
| Dec 31, 2025 | 165.08 Mn |
| Sep 30, 2025 | 189.76 Mn |
| Jun 30, 2025 | 224.50 Mn |
| Mar 31, 2025 | 165.14 Mn |
| Dec 31, 2024 | 185.05 Mn |
| Sep 30, 2024 | 204.41 Mn |
| Jun 30, 2024 | 217.42 Mn |
| Mar 31, 2024 | 240.46 Mn |
| Dec 31, 2023 | 253.65 Mn |
| Sep 30, 2023 | 173.29 Mn |
| Jun 30, 2023 | 184.64 Mn |
| Mar 31, 2023 | 103.45 Mn |
| Dec 31, 2022 | 116.97 Mn |
| Sep 30, 2022 | 91.68 Mn |
| Jun 30, 2022 | 102.02 Mn |
| Mar 31, 2022 | 113.66 Mn |
| Dec 31, 2021 | 126.34 Mn |
| Sep 30, 2021 | 122.64 Mn |
| Jun 30, 2021 | 106.93 Mn |